Mykola Sosiukin/iStock via Getty Images Altimmune Inc. (NASDAQ:ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss. The differentiating element compared to the competition seems to be the drug's ability to attack 74.5% fat mass and, if confirmed in the next phase 2 and phase 3 steps, could create a competitive moat against already approved drugs that act on the same GLP-1 hormone. The market prospects appear to b ...